Literature DB >> 16101154

Biochemical changes of mevalonate pathway in human colorectal cancer.

Maria Gabriella Caruso1, Maria Notarnicola.   

Abstract

BACKGROUND: Alterations in the mevalonate pathway may contribute to malignant cell growth. There are differences in the aetiology, clinical behaviour, pathological and genetic features in cancer of the right versus the left colon. Here, 3-hydroxy-3-methylglutatyl coenzyme A (HMG-CoA) reductase, farnesylpyrophosphate (FPP) synthase and farnesyltransferase (Ftase) activities were measured in human colorectal cancer (CRC) and normal mucosa in order to evaluate their role as potential markers of malignancy, also in relation to cancer location. PATIENTS AND METHODS: HMG-CoA reductase, FPP synthase and Ftase activities were determined in CRC and normal mucosa of 90 patients by radiochemical assay.
RESULTS: The enzymatic activities were higher in cancer than in normal mucosa. The tumours located at the left side showed higher HMG-CoA reductase activity, whereas the right side tumours showed higher levels of Ftase and FPP synthase activity.
CONCLUSION: The determination of mevalonate pathway enzymes in relation to CRC location may be clinically relevant in designing anticancer targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16101154

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.

Authors:  Jean-Pierre H Perchellet; Elisabeth M Perchellet; Kyle R Crow; Keith R Buszek; Neil Brown; Sampathkumar Ellappan; Ge Gao; Diheng Luo; Machiko Minatoya; Gerald H Lushington
Journal:  Int J Mol Med       Date:  2009-11       Impact factor: 4.101

2.  Dietary-suppression of hepatic lipogenic enzyme expression in intact male transgenic mice.

Authors:  Maria Notarnicola; Maria Gabriella Caruso; Angela Tafaro; Valeria Tutino; Giusy Bianco; Mario Minoia; Antonio Francavilla
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

3.  Polyunsaturated fatty acids reduce fatty acid synthase and hydroxy-methyl-glutaryl CoA-reductase gene expression and promote apoptosis in HepG2 cell line.

Authors:  Maria Notarnicola; Caterina Messa; Maria G Refolo; Valeria Tutino; Angelica Miccolis; Maria G Caruso
Journal:  Lipids Health Dis       Date:  2011-01-18       Impact factor: 3.876

4.  Multivariate explanatory model for sporadic carcinoma of the colon in Dukes' stages I and IIa.

Authors:  J M Villadiego-Sánchez; M Ortega-Calvo; R Pino-Mejías; A Cayuela; P Iglesias-Bonilla; F García-de la Corte; J M Santos-Lozano; José Lapetra-Peralta
Journal:  Int J Med Sci       Date:  2009-01-30       Impact factor: 3.738

5.  SREBP2 is upregulated in esophageal squamous cell carcinoma and co‑operates with c‑Myc to regulate HMGCR expression.

Authors:  Chenxi Zhong; Limin Fan; Zhigang Li; Feng Yao; Heng Zhao
Journal:  Mol Med Rep       Date:  2019-08-09       Impact factor: 2.952

Review 6.  Nutraceuticals as potential therapeutic agents for colon cancer: a review.

Authors:  Palaniselvam Kuppusamy; Mashitah M Yusoff; Gaanty Pragas Maniam; Solachuddin Jauhari Arief Ichwan; Ilavenil Soundharrajan; Natanamurugaraj Govindan
Journal:  Acta Pharm Sin B       Date:  2014-05-03       Impact factor: 11.413

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.